A 42-year-old woman from Mumbai is admitted to the ICU on day 8 of COVID-19 illness with severe pneumonia (PaO₂ 65 mmHg on FiO₂ 0.6, respiratory rate 32/min). Her D-dimer is elevated at 2.8 μg/mL (normal <0.5), and CT pulmonary angiography shows bilateral ground-glass opacities with no pulmonary embolism. Ferritin is 850 ng/mL, and IL-6 is markedly elevated. She is started on low-molecular-weight heparin (LMWH) for thromboprophylaxis. Which of the following best explains the prothrombotic state in severe COVID-19?

Explanation

## Prothrombotic State in Severe COVID-19 ### Pathophysiology of Thrombosis **Key Point:** The prothrombotic state in severe COVID-19 is driven by **endothelial cell damage and tissue factor (TF) exposure**, activating the extrinsic coagulation pathway and triggering a hypercoagulable state. ### Mechanism of Coagulation Activation **High-Yield:** SARS-CoV-2 causes direct endothelial injury through multiple pathways: 1. **Direct viral invasion** → ACE2 receptor-mediated endothelial cell infection 2. **Inflammatory cytokine storm** (IL-6, TNF-α, IL-1β) → endothelial dysfunction 3. **Tissue factor (TF) exposure** → activation of Factor VII → extrinsic pathway activation 4. **Platelet activation** → microthrombi formation in pulmonary and systemic circulation 5. **Fibrin deposition** → diffuse intravascular coagulation (DIC) in severe cases ### Cascade of Events in Severe COVID-19 ```mermaid flowchart TD A[SARS-CoV-2 infection]:::outcome --> B[Endothelial cell damage & ACE2 invasion]:::action B --> C[Tissue Factor exposure]:::action C --> D[Extrinsic pathway activation<br/>Factor VII activation]:::action D --> E[Thrombin generation & fibrin deposition]:::action E --> F[Platelet aggregation & microthrombi]:::action A --> G[Cytokine storm<br/>IL-6, TNF-α elevation]:::action G --> H[Enhanced endothelial permeability]:::action H --> F F --> I[Elevated D-dimer & fibrin degradation products]:::outcome F --> J[Pulmonary microthrombi & ARDS]:::urgent ``` ### Laboratory Markers of Hypercoagulability | Parameter | Finding in Severe COVID-19 | Clinical Significance | |-----------|----------------------------|----------------------| | D-dimer | Markedly elevated (>2 μg/mL) | Marker of thrombin generation and fibrin breakdown | | Ferritin | Elevated (>500 ng/mL) | Reflects systemic inflammation and endothelial damage | | IL-6 | Markedly elevated | Drives cytokine storm and coagulation activation | | Prothrombin time (PT) | Prolonged in severe cases | Consumption of clotting factors | | Platelet count | Variable; may be low in DIC | Platelet consumption in microthrombi | | Fibrinogen | Often elevated initially, then decreased | Consumption in DIC | **Clinical Pearl:** The **combination of elevated D-dimer + elevated ferritin + elevated IL-6** in a patient with severe COVID-19 is highly predictive of thrombotic complications and poor prognosis. This patient's profile fits this pattern. ### Role of Anticoagulation **Key Point:** Therapeutic or prophylactic anticoagulation (LMWH, UFH, or DOACs) is indicated in hospitalized COVID-19 patients because: - Prevents microthrombi formation - Reduces progression to DIC - Improves oxygenation and reduces mortality in severe cases - LMWH is preferred in ICU settings due to predictable pharmacokinetics ### Why This Patient Needs Anticoagulation This 42-year-old woman has: - **Severe hypoxemia** (PaO₂ 65 mmHg on FiO₂ 0.6) → indicates severe ARDS - **Elevated D-dimer** (2.8 μg/mL) → evidence of thrombin generation - **Elevated ferritin & IL-6** → systemic inflammation and endothelial damage - **Day 8 of illness** → peak risk period for thrombotic complications These findings indicate **endothelial-driven hypercoagulability**, not PE (CTPA negative), making LMWH prophylaxis appropriate.